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A B S T R A C T
Intractable temporal lobe epilepsy (TLE) is associated with alterations in expression of apoptosis-
associated signaling molecules in the temporal lobe. Bcl-2 is an anti-apoptotic molecule which has
previously been reported to be raised in patient’s brain and serum. In the present study we examined
serum Bcl-2 protein levels as a surrogate marker of apoptosis-associated signaling in children with non
lesional TLE. Serum Bcl-2 levels were found to be higher in patients with TLE than controls. The serum
level correlated to seizure variables including, duration of disease, frequency of seizures, and disease
severity. The impact of epilepsy on cognition was assessed using total score intelligence quotient (IQ). IQ
was found to be lower than controls and negatively correlated to serum Bcl-2. These ﬁndings support
serum Bcl-2 levels as a marker of seizure burden and cognition in children with epilepsy.
 2012 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Seizure
jou r nal h o mep age: w ww.els evier . co m/lo c ate /ys eiz1. Introduction
Epilepsy is the most common neurologic disorder affecting
people of all ages with up to 3% of the population suffering epilepsy
at some point in their lives.1 Temporal lobe epilepsy (TLE) is the
most common and most intractable epilepsy syndrome, and as
many as 70% of these patients are drug-refractory.2 Thus, one third
of TLE patients continue to experience seizures despite taking
antiepileptic drugs (AEDs).3
Seizures can be harmful to the brain. This is well established for
prolonged seizures and status epilepticus in animal models and
clinical studies, although it remains unresolved whether sponta-
neous (i.e. epileptic) seizures cause signiﬁcant neuron loss.4
However, the emergence of high-resolution neuroimaging of
patients has revealed damage progression in epilepsy patients
who continue to experience seizures.2 As a result, there has been
considerable interest in deﬁning the molecular pathways involved
in seizure-induced neuronal death. This may have implications for
therapeutic strategies not only to mitigate damage and cognitive
dysfunction in epilepsy but also inﬂuencing epileptogenesis after a
brain injury.5,6 Research on the mechanism, by which neurons die
after status epilepticus, has identiﬁed some hallmarks of apopto-
sis.5,6 In particular, upregulation of pro- and anti-apoptotic Bcl-2
family proteins in, both, resected TLE samples and experimental
models of seizure-induced neuronal death.7* Corresponding author at: Neuropsychiatry Department, Ain Shams University,
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doi:10.1016/j.seizure.2012.01.004The Bcl-2 gene family comprises more than 20 different members
that either positively or negatively regulate apoptosis.8 Bcl-2 family
proteins are typically small (20–30 kDa) and are deﬁned according
to the presence of one or more homology domains (BH domains).
Antiapoptotic members of the Bcl-2 family such as Bcl-2 and Bcl-xl
promote mitochondrial function and stabilization via direct actions
on mitochondrial membrane integrity, Ca2+ mobilization, and,
perhaps, antioxidant properties.9 Both pro- and anti-apoptotic Bcl-2
family proteins are also important in regulating endoplasmic
reticulum (ER)-based functions including ER-to-mitochondrial
Ca2+ signaling.10 Mitochondrial dysfunction and apoptosis proceed
when a subgroup of proapoptotic Bcl-2 family proteins called BH3-
only members is activated, for example by transcriptional activation
or post-translational modiﬁcation. This leads to disabling anti-
apoptotic members by dimerizing and/or directly activating multi-
domain Bax/Bak.8
Brain injury, subsequent to seizures, may result in detectable
levels of certain proteins in the cerebrospinal ﬂuid or plasma. In
the present study, we aimed to assess the levels of Bcl-2, as a
surrogate marker of apoptosis, in the sera of children with TLE and
to evaluate the impact of apoptosis on to assess cognitive
functions.
2. Subjects and methods
2.1. Subjects
Each local ethical committee of National Research Centre and
Ain Shams University approved the study. A legal written consentvier Ltd. All rights reserved.
Table 1
Characteristics of patients and control group.
Patients (30) Control (30) p
Age (years  SD) 10.03  3.16 10.1  2.74 0.93(NS)
Sex
Male 18 (60%) 20 (66.6%)
Female 12 (40%) 10 (33.4%) 0.81(NS)
IQ (intelligence quotient) 88.2  9.48 97.4  7.78 <0.001**
Consanguinity Non Non
Positive family history 3 (10%)
Number of affected sibs 1
Neonatal hyperbilirubinaemia 3 (10%)
Age at onset of
epilepsy (mean  SD)
8.8  3.3 years
Duration of illness
(months  SD)
15.2  6.9 months
Seizure control
Controlled 11 (36.6%)
Uncontrolled 19 (63.4%)
Frequency of seizure
(median/month)
1/month
Severity scale (mean  SD) 10.5  3.6
NS = non-signiﬁcant.
** Highly signiﬁcant.
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included 30 children and adolescents with non-lesional TLE (age
range 5–15 years). Their diagnosis was based on the criteria of
classiﬁcation of epileptic syndromes according to the Commission
on Classiﬁcation and Terminology of the International League
against Epilepsy.11 The patients (18 male and 12 female) were
recruited randomly from those attending the outpatient clinic,
Department of Research on Children with Special Needs, National
Research Centre. Thirty clinically healthy children and adolescents
with no history suggesting medical, neurological or psychiatric
disorders were included as the control group. They were, both, age
and sex matching the study group.
2.2. Exclusion criteria
Patients with lesional temporal lobe epilepsy, evidenced by
MRI, and those with evidence of intercurrent infections or with
other chronic illnesses known to affect apoptosis, e.g. autoimmune
disorders, were excluded from the study.
2.3. Methods
All cases were subjected to full clinical neurological evaluation
including:
 Age at onset of seizures.
 Frequency of seizures (number of events per month) and
duration of disease (in years).
 Type of seizure, whether partial or generalized according to
International League Against Epilepsy (ILAE) classiﬁcation.11
 Seizure severity according to The National Hospital Seizure
Severity Scale.12
 Anti-epileptic drugs received.
 Control of seizures on therapy; patients were considered
controlled if no seizure episodes occurred during the last
6 months.
 Presence of consanguinity and Family history of epilepsy
including febrile seizures.
A standard interictal awake and sleep 16 channels digital EEG
was performed for all cases, with a long-term EEG monitoring in
selected cases to assure the temporal focus. Magnetic Resonance
Imaging (MRI) study of the brain was done to all cases using
epilepsy protocol.13,14 Neuropsychological assessment of cognitive
function carried out using Wechsler intelligence scale for
children.15
2.4. Serum Bcl-2 protein level analysis
Measurement of the serum level of Bcl-2 was carried out using a
commercial enzyme linked immunosorbent assay technique
(ELISA) following the manufacturer’s instructions (Bender Med-
Systems GmbH, Austria). Blood was drawn from patients and
healthy controls during routine follow up of school children. The
samples were left to clot and sera were separated and stored at
70 8C until assay. Serum samples were assayed in duplicate. The
absorbance of each microwell was read at 450 nm using ELISA
reader STATFAX-2000. The concentration of Bcl-2 in a sample wasTable 2
Correlation between IQ and seizure parameters of studied patients.
Seizure parameters Duration Severity 
IQ r = 0.62 (p < 0.001)** r = 0.5 (p = 0
IQ = intelligent quotient. NS – non signiﬁcant.
** Highly signiﬁcant.determined by interpolation from a standard curve. The detection
limit for Bcl-2 assay was 0.5 ng/ml, with the intra-assay coefﬁcient
of variation 8.6%.
2.5. Statistical methods
Data were analyzed using SPSS, computer package, version 17
(SPSS, Chicago, IL, USA). Data are presented as mean  SD and
median (interquartile range) for normally distributed and non-
parametric data respectively. Student’s t-test was used for compari-
son of normally distributed data between groups. Spearman’s
correlation coefﬁcient was used to correlate various variables in
the studied groups. Multivariate regression analysis was used to
study correlation between multiple variables. For all tests p < 0.05
was considered to be statistically signiﬁcant.
3. Results
3.1. Clinical parameters
The study included 30 patients with non-lesional TLE with a
mean age of 10.03  3.16 years and 30 controls matched for age and
sex (Table 1). Three (10%) were included within 6 months of diagnosis
and only one patient (3.3%) after 36 months of diagnosis.
The mean age at onset of epilepsy in the patient group was
8.8  3.3 years and the average duration of illness was 15.2 
6.9 months. Seizures, in eleven cases, were controlled while 19 were
uncontrolled, with a median seizure frequency of one attack/month.
The mean seizure severity scale was 10.5  3.6 (Table 1).
The mean IQ was signiﬁcantly lower in the patient group
compared to the control group (Table 1). IQ showed a signiﬁcant
inverse association with seizure severity and duration, but it did
not correlate with either seizure frequency or age at onset of
epilepsy (Table 2). Multivariate regression analysis revealed that
IQ was related to duration of epilepsy only (t = 3.2 and p < 0.001).Frequency Age at onset
.005)** r = 0.22 (p = 0.25) NS r = 0.03 (p = 0.85) NS
Table 3
Difference between mean serum Bcl-2 levels in controlled and uncontrolled
patients.
Uncontrolled Controlled p value
Bcl-2 (ng/ml) 5.46  1 4.42  0.72 p = 0.003*
* Signiﬁcant.
Table 4
Correlation between mean Bcl-2 serum level and seizure parameters.
Seizure parameter r p
Bcl-2 Duration 0.68 p < 0.001**
Severity 0.96 p < 0.001**
Frequency 0.69 p < 0.001**
** Highly signiﬁcant.
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Fig. 1. Serum Bcl-2 of patients and controls. The ﬁgure represent the difference in
Bcl-2 serum level between case and control with signiﬁcantly higher level in cases
(p < 0.001).
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The serum levels of Bcl-2 were signiﬁcantly higher (p < 0.001)
in the patients (5.08  1.05 ng) compared to the control group
(2.27  0.65 ng) (Fig. 1). Within the patient group, serum Bcl-2 was
signiﬁcantly higher (p = 0.003) in uncontrolled patients (5.46  1 ng)
compared to controlled (4.42  0.72 ng) patients (Table 3). Bcl-2
serum level was found to correlate positively with seizure variables
including severity, frequency and duration (F = 11.61, 7.16, and 3.0
respectively) (Table 4). Multivariate regression analysis revealed
correlation only to severity (t = 5.0, p < 0.001) and duration (t = 3.4,
p = 0.02). Serum Bcl-2 levels were also found to be correlated
negatively with total score IQ in the patient group (r = 0.62 and
p < 0.001) (Fig. 2).IQ
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Fig. 2. Correlation between serum Bcl-2 level and IQ of patients. The correlation
between IQ and serum Bcl-2 of cases is a negative correlation (r = 0.6) with a
statistically signiﬁcant p value (p < 0.001).4. Discussion
Recurrent seizures may pose a risk of injury to the brain.2,13 The
mechanism of neuronal death after brief seizures is not fully
understood but may involve activation of apoptosis-associated
signaling pathways.5,6 Indeed, temporal lobe cortex and hippo-
campus from adults and children with refractory epilepsy show
raised levels of both pro- and anti-apoptotic proteins, including
Bcl-2.6 In the present study we assayed serum Bcl-2 levels in
children with TLE. We detected elevated Bcl-2 levels in epileptic
patients and more elevated levels in patients with uncontrolled
versus controlled seizures. Bcl-2 levels also correlated negatively
with IQ. Taken together, these data suggest that epileptic seizures
may inﬂuence expression of Bcl-2, either centrally or peripherally,
and Bcl-2 may serve as a surrogate marker of apoptosis, caused by
epileptic seizures, and their sequelae.
Bcl-2 is an important anti-apoptotic protein which is upregu-
lated in surviving cell populations following injury from ischemia,
trauma, and seizures.16 Several studies have reported increased
Bcl-2 levels in temporal lobe material from patients with epilepsy,
including children.6,7 Bcl-2 up-regulation appears to be in
neurons.5 Whether this represents a protective adaptation is
unknown although experimental delivery of Bcl-2 potently
protects against neuronal apoptosis.17 Thus, upregulation of Bcl-
2 may be an adaptive response to seizure stress which contributes
to limiting ongoing neuron loss.
Experimental and human data suggest hippocampal damage in
TLE is mainly a consequence of an initial precipitating injury.18,19
Nevertheless, evidence of a correlation between repeated brief
seizures, brain damage, and the resulting cognitive deﬁcit has been
provided from animal models of TLE. Kotloski et al.20 reported that
cognitive deﬁcits, after repeated seizures in rats, were in
proportion to damage to the hippocampus. This study and other
experimental and human data21,22 support the view that
hippocampal sclerosis and associated memory dysfunction may
be worsened by repeated seizures, and imply that seizure control
could prevent adverse long-term consequences of seizures on
hippocampal-dependent functions.
Ten percent of cases were found to have positive family history
of other affected members. Two, non related, patients have another
affected sib. The other patient has two, affected, family members;
his sib and a ﬁrst cousin. They were, all, outcome of non-
consanguineous marriage up to the grandparents. Pedigree
analysis of our cases pointed to a possible autosomal dominant
trait. Absence of vertical transmission could be explained by
reduced penetrance due to modiﬁer genes and environmental
interaction.23
Two types of familial temporal lobe epilepsies (FTLE) were
described based on seizure semiology, genetic background, and
MRI characteristics namely the mesial (FMTLE) and the lateral
(FLTLE) forms.11 The ﬁnding of at least two TLE patients in one
family is suggestive of FTLE.24 An autosomal-dominant pattern
of inheritance with incomplete penetrance, autosomal-recessive
or sex linked inheritance cannot be ruled out in some
families.23,24
The ﬁrst major ﬁnding in the present study was that serum Bcl-
2 levels were elevated in children with epilepsy. Our study also
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control compared to those where seizures were managed. Notably,
serum Bcl-2 levels correlated positively with the severity and
frequency of seizures as well as with the duration of epilepsy. On
the other hand, Henshall et al.25 reported that brain levels of the
related Bcl-2 family protein, Bcl-xL correlated positively with
seizure frequency, although Bcl-2 levels did not. Cherian et al.,26
also, reported extensive apoptosis in association with intractable
status epilepticus in the resected brain specimen of an 8 1/2-
month-old girl. This would be in agreement with experimental
work that detected apoptosis-related proteins in the CSF following
status epilepticus in rats Murphy et al.27 Determining whether
serum bcl-2 represents protein released as a result of tissue
damage will be an important next step. We, also, know that Bcl-2 is
not the only apoptosis-related protein which can be detected in
serum in epilepsy.14 Identiﬁcation of other, potentially more
sensitive serum proteins from among the apoptosis-related
protein network will be valuable in extending the present work.
Our ﬁndings compliment and extend previous work which
investigated serum markers of apoptosis in children with
epilepsy.14 El-Hodhod et al.14 reported an elevated serum levels
of Bcl-2 in patients with idiopathic epilepsy and were related to the
seizure severity and frequency.14 As none of the patients in our
study had lesional epilepsy, therefore, the raised serum Bcl-2
appears to be a consistent peripheral marker of epilepsy in
children. The patient group in the El-Hodhod et al.14 study was also
less homogenous, comprising individuals with focal, focal with
secondary generalization, and generalized seizures. Their patients
were, also, on both mono- and polytherapy without speciﬁcation.
In contrast, our patient group represented a single epileptic
syndrome on monotherapy (Carbamazepine).
A second important ﬁnding in the present study were the
correlation between Bcl-2 serum level and total IQ score, in
addition to seizure parameters. Thus, serum Bcl-2 levels were
inversely correlated with IQ. The total IQ scores for patients were
signiﬁcantly lower than control and the predictive values were,
namely, duration of epilepsy and severity of attacks. One
interpretation of this data is that the longer the duration and
the more severe the seizures the worse the negative impact on
cognition. If serum Bcl-2 is a reliable biomarker of seizure activity
then it may represent a novel means for tracking cognitive affects
of seizures. Whether raised Bcl-2 levels in patient sera confer any
protective effects on the brain is, currently, unknown. Our data
are congruent with other ﬁndings on seizures and cognition in
children. Stable aspects of cognitive function, such as IQ, are most
closely related to the severity of the epilepsy syndrome
(including average seizure frequency).21 Thus seizures, which
are known to have a direct transient effect on cognitive aspects,
can affect stable cognitive aspects and the intelligence level.
Desai28 found that the most predictive parameters for cognitive
impairment were age of onset, frequency of seizures, and
duration of epilepsy. Our study was concordant with this as
regards the duration of epilepsy being the strongest predictor. In
addition there was a modest difference between IQ of controlled
patients and patients with frequent seizures, although this did
not reach signiﬁcance (p = 0.09). Thus, epilepsy occurring in early
childhood is frequently associated with considerable cognitive
and behavioral morbidity.29,30
In summary, we found that serum Bcl-2 levels are elevated in
children with TLE and is further increased in drug refractory
patients. Although we do not know if it is derived directly from
damaged CNS tissue or due to peripheral (e.g. immune) responses
to seizures or other mechanisms, Bcl-2 could be a useful surrogate
marker of progressive versus non-progressive epilepsy. Our study,
also, highlights the potentially negative impact of seizures oncognitive function, supporting the need for better seizure
management for children with TLE.
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